Effects of Carnosine In Patients With Peripheral Arterial Disease Patients

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

Also called NCT06480760

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 1/2
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06480760
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06480760. Randomized; triple masking; primary purpose treatment. Start 2025-05-20 (actual); primary completion 2028-10-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Carnosine In Patients With Peripheral Arterial Disease Patients
Acronym
CIPHER
Condition
Peripheral Arterial Disease
Intervention (Drug)
Carnosine
Lead sponsor
Shahid Baba (class: other)
Collaborator
National Institutes of Health (NIH) (class: US National Institutes of Health)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct06480760
Content hash
0dd365df1d0abd9a239d4f7977f792f26e7a22113b341a11814d7bb75665ded7